Download PDF
Semin Thromb Hemost 2019; 45(04): 348-353
DOI: 10.1055/s-0039-1687893
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Thrombotic Microangiopathy in Cancer

Ilene Ceil Weitz
1   Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California-Keck School of Medicine, Los Angeles, California
› Author Affiliations
Further Information

Publication History

Publication Date:
30 April 2019 (online)

    Permissions and Reprints

Abstract

Thrombotic microangiopathy (TMA) is a rare but often devastating complication of cancer and cancer treatment. The syndrome is defined by thrombocytopenia (i.e., a platelet count of < 150,000/mcL or > 30% decrease from baseline), microangiopathic hemolytic anemia, and some evidence of organ damage. Among the nine recognized groups of disorders causing TMA, the focus of this article will be on cancer and cancer treatment-related causes of TMA. This review will discuss the pathophysiology of TMA in cancer, chemotherapy-associated TMA, transplant-associated TMA, and newer therapeutic modalities.

Keywords

thrombotic microangiopathy - cancer - hematopoietic stem cell transplantation - eculizumab

Addendum

This review represents a more comprehensive and updated review to one recently published by this author.[74] Some short excerpts of text have been reproduced with the permission of the publisher.[74]


 

  • References

  • 1 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347 (08) 589-600
    CrossrefPubMedGoogle Scholar
  • 2 George JN, Nestor CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371: 54-66
    PubMedGoogle Scholar
  • 3 Brain MC, Azzopardi JG, Baker LR, Pineo GF, Roberts PD, Dacie JV. Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma. Br J Haematol 1970; 18 (02) 183-193
    CrossrefPubMedGoogle Scholar
  • 4 Lohrmann HP, Adam W, Heymer B, Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 1973; 79 (03) 368-375
    PubMedGoogle Scholar
  • 5 Antman KH, Skarin AT, Mayer RJ, Hargreaves HK, Canellos GP. Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore) 1979; 58 (05) 377-384
    CrossrefPubMedGoogle Scholar
  • 6 Coppola A, Davi G, De Stefano V, Mancini FP, Cerbone AM, Di Minno G. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000; 26 (03) 243-254
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Francis KK, Kojouri K, George JN. Occult systemic carcinoma masquerading as thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Community Oncol 2005; 2: 339-343
    CrossrefPubMedGoogle Scholar
  • 8 Lesesne JB, Rothschild N, Erickson B. , et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7 (06) 781-789
    CrossrefPubMedGoogle Scholar
  • 9 Story M, Kwon SK, Robinson R, Fortis S. Acute cor pulmonale due to pulmonary tumour thrombotic microangiopathy from renal cell carcinoma. BMJ Case Rep 2017; 2017: bcr-2017-bcr-219730
    PubMedGoogle Scholar
  • 10 von Herbay A, Illes A, Waldherr R, Otto HF. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer 1990; 66 (03) 587-592
    CrossrefPubMedGoogle Scholar
  • 11 Marumo S, Sakaguchi M, Teranishi T, Higami Y, Koshimo Y, Kato M. Pulmonary tumor thrombotic microangiopathy induced by ureteral carcinoma: a necropsy case report. Case Rep Oncol 2014; 7 (02) 605-610
    CrossrefPubMedGoogle Scholar
  • 12 Patrignani A, Purcaro A, Calcagnoli F, Mandolesi A, Bearzi I, Ciampani N. Pulmonary tumor thrombotic microangiopathy: the challenge of the antemortem diagnosis. J Cardiovasc Med (Hagerstown) 2014; 15 (11) 828-833
    CrossrefPubMedGoogle Scholar
  • 13 Dean SA, Mathis B, Litzky LA, Hood IC. Sudden death by occult metastatic carcinoma. J Forensic Sci 2015; 60 (06) 1637-1639
    CrossrefPubMedGoogle Scholar
  • 14 Abe H, Hino R, Fukayama M. Platelet-derived growth factor-A and vascular endothelial growth factor-C contribute to the development of pulmonary tumor thrombotic microangiopathy in gastric cancer. Virchows Arch 2013; 462 (05) 523-531
    CrossrefPubMedGoogle Scholar
  • 15 Hotta M, Ishida M, Kojima F, Iwai Y, Okabe H. Pulmonary tumor thrombotic microangiopathy caused by lung adenocarcinoma: case report with review of the literature. Oncol Lett 2011; 2 (03) 435-437
    CrossrefPubMedGoogle Scholar
  • 16 Zwicker JI, Liebman HA, Neuberg D. , et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15 (22) 6830-6840
    CrossrefPubMedGoogle Scholar
  • 17 Ishida Y, Yamashita K, Sasaki H. , et al. Activation of complement system in adult T-cell leukemia (ATL) occurs mainly through lectin pathway: a serum proteomic approach using mass spectrometry. Cancer Lett 2008; 271 (01) 167-177
    CrossrefPubMedGoogle Scholar
  • 18 Suryawanshi S, Huang X, Elishaev E. , et al. Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 2014; 20 (23) 6163-6174
    CrossrefPubMedGoogle Scholar
  • 19 Sussman T, Abazeed M, McCrae K, Khorana AA. RNA sequencing approaches to identifying novel biomarkers for thromboembolism (VTE) in lung cancer. Blood 2017; 130: 291
    PubMedGoogle Scholar
  • 20 Khan MA, Assiri AM, Broering DC. Complement and macrophage crosstalk during process of angiogenesis in tumor progression. J Biomed Sci 2015; 22 (01) 58
    CrossrefPubMedGoogle Scholar
  • 21 Nunez-Cruz S, Gimotty PA, Guerra MW. , et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 2012; 14 (11) 994-1004
    CrossrefPubMedGoogle Scholar
  • 22 Davila M, Amirkhosravi A, Coll E. , et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008; 6 (09) 1517-1524
    CrossrefPubMedGoogle Scholar
  • 23 Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, López JA. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost 2007; 5 (01) 70-74
    CrossrefPubMedGoogle Scholar
  • 24 Levi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006; 32 (01) 33-39
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Krisinger MJ, Goebeler V, Lu Z. , et al. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 2012; 120 (08) 1717-1725
    PubMedGoogle Scholar
  • 26 Huber-Lang M, Sarma JV, Zetoune FS. , et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12 (06) 682-687
    CrossrefPubMedGoogle Scholar
  • 27 Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96 (12) 1233-1239
    CrossrefPubMedGoogle Scholar
  • 28 Zipfel PF, Hallström T, Riesbeck K. Human complement control and complement evasion by pathogenic microbes--tipping the balance. Mol Immunol 2013; 56 (03) 152-160
    CrossrefPubMedGoogle Scholar
  • 29 Ritis K, Doumas M, Mastellos D. , et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006; 177 (07) 4794-4802
    CrossrefPubMedGoogle Scholar
  • 30 Landsem A, Nielsen EW, Fure H. , et al. C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood. Clin Exp Immunol 2013; 173 (02) 217-229
    CrossrefPubMedGoogle Scholar
  • 31 Griffin PT, Jaglal M. Metastatic prostate cancer mimicking thrombotic thrombocytopenic purpura. Blood 2015; 125 (08) 1349
    CrossrefPubMedGoogle Scholar
  • 32 Verweij J, van der Burg ME, Pinedo HM. Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol 1987; 8 (01) 33-41
    CrossrefPubMedGoogle Scholar
  • 33 Grangé S, Coppo P. ; Centre de référence des microangiopathies thrombotiques (CNR-MAT). Thrombotic microangiopathies and antineoplastic agents. Nephrol Ther 2017; 13 (Suppl. 01) S109-S113
    CrossrefPubMedGoogle Scholar
  • 34 Izzedine H, Isnard-Bagnis C, Launay-Vacher V. , et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 2006; 21 (11) 3038-3045
    CrossrefPubMedGoogle Scholar
  • 35 Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 2007; 8 (07) 634-641
    CrossrefPubMedGoogle Scholar
  • 36 Thurnher D, Kletzmayr J, Formanek M. , et al. Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx. Oncology 2001; 61 (02) 143-146
    CrossrefPubMedGoogle Scholar
  • 37 Walker RW, Rosenblum MK, Kempin SJ, Christian MC. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 1989; 64 (05) 1017-1020
    CrossrefPubMedGoogle Scholar
  • 38 Nuver J, De Haas EC, Van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010; 23 (01) 247-253
    PubMedGoogle Scholar
  • 39 Izzedine H, Escudier B, Lhomme C. , et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore) 2014; 93 (24) 333-339
    PubMedGoogle Scholar
  • 40 Eremina V, Jefferson JA, Kowalewska J. , et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358 (11) 1129-1136
    CrossrefPubMedGoogle Scholar
  • 41 Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy, and reversible leukoencephalopathy. Ann Oncol 2007; 18 (10) 1745-1747
    CrossrefPubMedGoogle Scholar
  • 42 Martino S, Daguindau E, Ferrand C. , et al. A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib. Leuk Res Rep 2013; 2 (01) 29-31
    PubMedGoogle Scholar
  • 43 Ojeda-Uribe M, Merieau S, Guillon M. , et al. Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate. J Oncol Pharm Pract 2016; 22 (02) 361-370
    CrossrefPubMedGoogle Scholar
  • 44 Choi MK, Hong JY, Jang JH, Lim HY. TTP-HUS associated with sunitinib. Cancer Res Treat 2008; 40 (04) 211-213
    CrossrefPubMedGoogle Scholar
  • 45 Faguer S, Huart A, Frémeaux-Bacchi V, Ribes D, Chauveau D. Eculizumab and drug-induced haemolytic-uraemic syndrome. Clin Kidney J 2013; 6 (05) 484-485
    CrossrefPubMedGoogle Scholar
  • 46 Al Ustwani O, Lohr J, Dy G. , et al. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol 2014; 5 (01) E30-E33
    PubMedGoogle Scholar
  • 47 Weitz IC, Deloughrey T. Effective treatment of chemotherapy induced atypical haemolytic uraemic syndrome with eculizumab: a case series of 7 treated patients. Brit J Hematol 2018; 183 (01) 136-139
    CrossrefPubMedGoogle Scholar
  • 48 Sartelet H, Toupance O, Lorenzato M. , et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5 (10) 2441-2447
    CrossrefPubMedGoogle Scholar
  • 49 Pfister F, Amann K, Daniel C, Klewer M, Büttner A, Büttner-Herold M. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology 2018; 73 (06) 990-1001
    CrossrefPubMedGoogle Scholar
  • 50 Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009; 122 (04) 322-328
    CrossrefPubMedGoogle Scholar
  • 51 Eremina V, Sood M, Haigh J. , et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111 (05) 707-716
    CrossrefPubMedGoogle Scholar
  • 52 Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001; 8 (05) 286-293
    CrossrefPubMedGoogle Scholar
  • 53 Catalan SR, Yang S, Wu H. The use of ADAMTS13, platelet count and serum creatinine to differentiate acquired TTP and other thrombotic microangiopathies. Br J Haematol 2012; 157: 493-516
    CrossrefPubMedGoogle Scholar
  • 54 Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JAK, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3 (07) 1432-1436
    CrossrefPubMedGoogle Scholar
  • 55 Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015; 125 (04) 616-618
    CrossrefPubMedGoogle Scholar
  • 56 Reese JA, Bougie DW, Curtis BR. , et al. Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the BloodCenter of Wisconsin. Am J Hematol 2015; 90 (05) 406-410
    CrossrefPubMedGoogle Scholar
  • 57 Sartain S, Shubert S, Wu MF. , et al. Therapeutic plasma exchange does not improve renal function in hematopoietic stem cell transplantation-associated thrombotic microangiopathy: an institutional experience. Biol Blood Marrow Transplant 2018
    PubMedGoogle Scholar
  • 58 Shayani S, Palmer J, Stiller T. , et al. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2013; 19 (02) 298-304
    CrossrefPubMedGoogle Scholar
  • 59 Labrador J, López-Corral L, López-Godino O. , et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplant 2014; 49 (05) 684-690
    CrossrefPubMedGoogle Scholar
  • 60 Glezerman IG, Jhaveri KD, Watson TH. , et al. Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16 (07) 976-984
    CrossrefPubMedGoogle Scholar
  • 61 Laskin BL, Maisel J, Goebel J. , et al. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation 2013; 96 (02) 217-223
    CrossrefPubMedGoogle Scholar
  • 62 Jodele S, Dandoy CE, Myers K. , et al. High dose Carboplatin/Etoposide/Melphalan increases the risk of thrombotic microangiopathy and organ damage after autologous stem cell transplantation. Bone Marrow Transplant 2018; 53 (10) 1311-1318
    CrossrefPubMedGoogle Scholar
  • 63 Rotz SJ, Luebbering N, Dixon BP. , et al. In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy. Blood Adv 2017; 1 (20) 1632-1634
    CrossrefPubMedGoogle Scholar
  • 64 Jodele S, Laskin BL, Dandoy CE. , et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015; 29 (03) 191-204
    CrossrefPubMedGoogle Scholar
  • 65 Gavriilaki E, Sakellari I, Batsis I. , et al. Transplant-associated thrombotic microangiopathy: incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation. Clin Transplant 2018; 32 (09) e13371
    CrossrefPubMedGoogle Scholar
  • 66 Elsallabi O, Bhatt VR, Dhakal P, Foster KW, Tendulkar KK. Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2016; 22 (01) 12-20
    CrossrefPubMedGoogle Scholar
  • 67 Laskin BL, Goebel J, Davies SM. , et al. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant 2011; 46 (05) 682-689
    CrossrefPubMedGoogle Scholar
  • 68 Jodele S, Davies SM, Lane A. , et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124 (04) 645-653
    PubMedGoogle Scholar
  • 69 Ostronoff M, Ostronoff F, Calixto R. , et al. Life- threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant an allogeneic bone marrow transplant recipient. Bone Marrow Transplant 2007; 39: 649-651
    CrossrefPubMedGoogle Scholar
  • 70 Corti P, Uderzo C, Tagliabue A. , et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant 2002; 29 (06) 542-543
    CrossrefPubMedGoogle Scholar
  • 71 Jodele S, Licht C, Goebel J. , et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013; 122 (12) 2003-2007
    PubMedGoogle Scholar
  • 72 Jodele S, Zhang K, Zou F. , et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 2016; 127: 989-996
    CrossrefPubMedGoogle Scholar
  • 73 Jodele S, Fukuda T, Vinks A. , et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014; 20 (04) 518-525
    CrossrefPubMedGoogle Scholar
  • 74 Weitz IC. Thrombotic microangiopathy in cancer. Thromb Res 2018; 164 (Suppl. 01) S103-S105
    CrossrefPubMedGoogle Scholar